ESR1 and breast cancer: The combination of palbociclib with endocrine therapy has synergistic effects in ER+ human breast cancer cell lines [10] as well as xenograft models, and in tamoxifen-resistant breast tumor, the synergy is also present between palbociclib and selective estrogen receptor downregulator [11].